Renowned mining journalist Barry FitzGerald leads Stockhead’s deep dive into the critical minerals sector in this special investor guide.
Inflation’s cooling but still sticky, keeping rate cut hopes alive; meanwhile Trump’s back throwing punches at the Fed.
US-focused device maker Impedimed is building a $1.2 million stockpile of Asian-sourced componentry to avoid any fallout from Trump’s tariffs.
The smart money says Donald Trump’s protectionist policies have shattered a well-worn investing strategy.
Orthocell has received its third regulatory approval for April after getting the green light to sell its flagship nerve repair product Remplir into Canada.
